MannKind Corporation (NASDAQ:MNKD) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET
Company Participants
Michael Castagna - Chief Executive Officer
Steve Binder - Executive Vice President and Former Chief Financial Officer
Chris Prentiss - Chief Financial Officer
Conference Call Participants
Steve Lichtman - Oppenheimer and Co
Thomas Smith - Leerink Partners
Operator
Good afternoon, and welcome to the MannKind Corporation 2024 First Quarter Financial Results Earnings Call. As a reminder, this call is being recorded on May 8th, 2024, and will be available for playback on the MannKind Corporation website shortly after the conclusion of this call until May 22nd, 2024.
This call will contain forward-looking statements. Such forward-looking statements are subject to risks and uncertainty, which can cause actual risks to differ materially from these stated expectations. For further information on the Company's risk factors, please see the 10-Q report filed with the Securities and Exchange Commission this afternoon. The earnings release, and the slides prepared for this presentation.
Joining us today for MannKind are Chief Executive Officer, Michael Castagna; EVP, and Former Chief Financial Officer Stephen Binder; and Chief Financial Officer, Chris Prentiss.
I'd like to turn the conference over to Mr. Castagna. Please go ahead, sir.
Michael Castagna
Good evening, everyone, and welcome to my 28th earnings call. I'm thrilled to report another exceptional quarter of growth for MannKind. Over the past eight quarters, our revenue has surged by over 250%, a testament to the dedication and innovation of our team. This puts us on a run rate of over $250 million in revenue for 2024.
We have made tremendous progress in the field of inhaled insulin that we believe will continue to be a growth driver for years to come. I'm also excited to share with you our progress in addressing rare orphan lung diseases today. Thank you for joining us on this journey of growth and societal impact around the world.
Just to remind everyone, our mission at MannKind is to give people control of their health and the freedom to live life. When we think about that, it translates into how our products make a meaningful impact on patients every single day. As I look at Q1, we had a record Tabesa DPI revenue of almost $48 million due to strong sales by United Therapeutics and record production in Q1 as we continue to scale up the expansion facility we've been building over the last several years.